Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
WALTHAM, MA—Beskrovnaya Oxana, the Chief Scientific Officer of Dyne Therapeutics, Inc. (NASDAQ:DYN), recently sold 2,153 shares of the company’s common stock. The shares were sold at an average price of $11.38, generating a total of $24,501. The transaction comes as DYN trades near its 52-week low of $11.18, with InvestingPro analysis indicating the stock is currently undervalued. Analysts maintain a bullish outlook, with price targets ranging from $18 to $66. Following this transaction, Oxana holds 195,840 shares in the company, which includes 152,839 unvested restricted stock units.
The sale was executed on March 11, 2025, as part of a pre-arranged plan to cover tax withholding obligations linked to the vesting of restricted stock units granted in December 2021 and December 2022. This automatic sale is in line with a binding contract, ensuring compliance with Rule 10b5-1, and does not reflect a discretionary trade by Oxana.
In other recent news, Dyne Therapeutics has received significant attention from various analysts following its latest clinical developments and financial maneuvers. The company ended 2024 with a substantial cash reserve of approximately $642.3 million and further bolstered its finances by raising an additional $140.6 million through share issuance, positioning it well into the second half of 2026. Dyne is progressing with its clinical trials, notably with DYNE-251 for Duchenne muscular dystrophy (DMD) and DYNE-101 for myotonic dystrophy type 1 (DM1), with key data expected in 2025 and 2026.
Analyst firms have responded with mixed adjustments to their price targets. BMO Capital and Scotiabank (TSX:BNS) have both initiated coverage with an Outperform rating and a $50 price target, reflecting confidence in Dyne’s potential. H.C. Wainwright adjusted its target to $46, maintaining a Buy rating, while Piper Sandler reduced its target to $48 but kept an Overweight rating, citing strategic funding and promising clinical developments. Oppenheimer maintained a $60 target and an Outperform rating, highlighting the Fast Track Designation granted by the FDA for DYNE-101 as a key milestone.
These recent developments underscore the anticipation surrounding Dyne’s upcoming clinical readouts and potential regulatory submissions, which could significantly impact its market trajectory. Investors are closely watching the company’s progress in its clinical trials, as well as its strategic financial decisions, which analysts suggest could lead to accelerated approvals and potential market entry by 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.